Vertex Pharmaceuticals price target raised to $420 from $408 at RBC Capital
RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.
Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...
Vertex non-opioid painkiller Journavx gets mixed ICER review
The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex ...
Vertex Pharmaceuticals price target raised to $567 from $555 at BofA
BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...
The Motley Fool23d
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...
BioPharma Dive28d
Vertex’s new pain drug gets first coverage nod from major insurer
Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...